2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.
Wednesday, May 29, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: The 2024 ASCO presentation discusses the identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer. This study evaluates the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine and nab-paclitaxel. The findings from the Phase 2 study could lead to improved therapeutic strategies.
Market Sentiment Analysis
POSITIVE FACTORS
Identification of immune biomarkers could enhance treatment efficacy.
Combination therapy shows promise for treatment-naive patients.
Phase 2 study indicates progress in metastatic pancreatic cancer research.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
9.4%
average across 4 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
9-ING-41
Phase 2 · Cancer
Full Press Release Details
2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Download PDF View Resource
Frequently Asked Questions
What is the focus of the 2024 ASCO presentation?
The presentation focuses on identifying immune biomarkers in treatment-naive patients with metastatic pancreatic cancer.
What treatment is being studied in the Phase 2 trial?
The study evaluates the GSK-3 inhibitor elraglusib in combination with gemcitabine and nab-paclitaxel.
Who are the patients involved in the study?
The study involves treatment-naive patients diagnosed with metastatic pancreatic cancer.
What is the significance of immune biomarkers?
Identifying immune biomarkers could enhance the efficacy of treatments for pancreatic cancer.